4046-74-6

Usage

InChI:InChI=1/C13H10O3/c1-7-3-13(14)16-12-6-11-9(5-10(7)12)4-8(2)15-11/h3-6H,1-2H3

Upstream product

• 144780-75-6 7-acetoxy-6-bromomethyl-4-methylbenzopyran-2(H)-one 
• 90370-17-5 7-acetoxy-4,6-dimethyl benzopyran-2(H)-one 
• 3993-57-5 7-allyloxy-4-methyl-2H-chromen-2-one 
• 3993-50-8 4-methyl-6-allyl-7-acetoxycoumarin 
• 1616-53-1 6-allyl-7-hydroxy-4-methyl-2H-1-benzopyran-2-one 
• 3993-51-9 4-methyl-6-(2',3'-dibromopropyl)-7-acetoxycoumarin 

Relevant academic research and scientific papers

Treatment methods for lymes disease and associated debilitating conditions

A method is provided for treating human patients who have Lymes disease by using a psoralen compound, preferably administered in a dosage of 0.3 to 0.7 mg/kg, and activating same either in vitro or in vivo using electromagnetic radiation of a prescribed activating wavelength. The activation of the psoralen compound in the presence of a blood fraction from a patient suffering from Lymes disease produces a composition which will stimulate an effective immune response to the Lymes disease on the part of the patient.

Synthesis of linear and angular furocoumarins using intramolecular Wittig reaction: Part 31

Synthesis of linear and angular furocoumarins has been achieved from 7-acetoxy-6-bromomethyl-4-methylbenzopyran-2(H)-one (2a) using intramolecular Wittig reaction.Linear and angular furocoumarins having phenyl substituent at 2-position have been synthesis

Treatment methods and vaccines for stimulating an immunological response against retroviruses

Human Immunodeficiency Virus infections, particularly AIDS, are treated by administering a psoralen compound which is subsequently activated by exposure to electromagnetic radiation (e.g. UVA light) whereby the activated psoralen compound attacks free virus and/or virus infected cells in the blood of the patient. The treated blood when presented to the patient's immune system engenders an effective immune response against the infection. The method has particular utility in the treatment of ARC patients who have depressed immune function.